Compare TDAY & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDAY | SPTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | 2026 |
| Metric | TDAY | SPTX |
|---|---|---|
| Price | $6.36 | $24.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 109.3K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.56 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $1,526,024,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.54 | $17.59 |
| 52 Week High | $9.21 | $28.38 |
| Indicator | TDAY | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 51.93 |
| Support Level | $5.76 | $23.23 |
| Resistance Level | $6.65 | $28.38 |
| Average True Range (ATR) | 0.31 | 2.15 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 41.80 | 16.79 |
USA Today Co Inc is a diversified media company with national and local reach, dedicated to empowering and enriching communities. It prioritizes a digital-first approach, focusing on audience growth and engagement while diversifying revenue streams. Through its trusted brands, including the USA TODAY NETWORK, comprised of the national publication, USA TODAY, and local media organizations, including a network of local properties, in the United States, and Newsquest, a wholly-owned subsidiary operating in the United Kingdom, provide essential journalism, local content, and digital experiences to audiences and businesses. Its digital marketing solutions brand, LocaliQ, supports small and medium-sized businesses with digital marketing products and solutions.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.